KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function

Cardiovascular Research

Volumn 83, Issue 3, 2009, Pages 444-456

  Gao, Shan ^a,b   Long, Chao Liang ^a   Wang, Ru Huan ^c   Wang, Hai ^a,c,d  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c Thadweik Academy of Medicine   (China)

^d INSTITUTE OF HEALTH AND ENVIRONMENTAL MEDICINE   (China)

Author keywords

ATP sensitive potassium channel opener; Cardiac remodelling; Endothelial function; Iptakalim; Pressure overload

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; HYDROXYPROLINE; IPTAKALIM; LISINOPRIL; NITRIC OXIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CAROTID ARTERY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE VOLUME; HYPERTENSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SYSTOLIC DYSFUNCTION;

ANIMALS; AORTA, ABDOMINAL; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FIBROSIS; HEART FAILURE; HEART RATE; HYDROXYPROLINE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KATP CHANNELS; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TIME FACTORS; VENTRICULAR REMODELING;

EID: 67651124964     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp099     Document Type: Article

References (48)

1. Howell SJ, Sear JW, Foex P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 2004;92:570-583.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289:2560-2572.
3. Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res 2005; 28:191-202.
4. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;117:568-575.
5. Date M, Morita T, Yamashita N, Nishida K, Yamaguchi O, Higuchi Y et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol 2002;39:907-912.
6. Frohlich ED. Local hemodynamic changes in hypertension: insights for therapeutic preservation of target organs. Hypertension 2001;38: 1388-1394.
7. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001;104:1286-1291.
8. Kobayashi N, Mori Y, Nakano S, Tsubokou Y, Shirataki H, Matsuoka H. Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2001;19:795-801.
9. van Zwieten PA. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. Cardiovasc Res 2000;45:82-91.
10. Wang H, Zhang YL, Chen YP. Targeting small arteries of hypertensive status with novel ATP-sensitive potassium channel openers. Curr Vasc Pharmacol 2005;3:119-124.
11. Wang H, Tang Y, Wang L, Long CL, Zhang YL. ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives. Curr Med Chem 2007;14:133-155.
12. Wang H, Long CL, Zhang YL. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. J Pharmacol Exp Ther 2005;312:1326-1333.
13. Wang H. Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride, and its molecular mechanisms. Drug Dev Res 2003;58:65-68.
14. Wang H, Long CL, Duan ZB, Shi CG, Jai GD, Zhang YL. A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res 2007;73:497-503.
15. Minamino T, Hori M. Protecting endothelial function: a novel therapeutic target of ATP-sensitive potassium channel openers. Cardiovasc Res 2007; 73:448-449.
16. Dhalla NS, Golfman L, Liu X, Sasaki H, Elimban V, Rupp H. Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Ann N Y Acad Sci 1999;874:100-110.
17. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67:1355-1364.
18. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138.
19. Veltkamp R, Rajapakse N, Robins G, Puskar M, Shimizu K, Busija D. Transient focal ischemia increases endothelial nitric oxide synthase in cerebral blood vessels. Stroke 2002;33:2704-2710.
20. Ozono R, Matsumoto T, Shingu T, Oshima T, Teranishi Y, Kambe M et al. Expression and localization of angiotensin subtype receptor proteins in the hypertensive rat heart. Am J Physiol Regul Integr Comp Physiol 2000;278:R781-R789.
21. Grantham JA, Burnett JC Jr. BNP: increasing importance in the pathophysiology and diagnosis of congestive heart failure. Circulation 1997;96: 388-390.
22. Ciobotaru V, Heimburger M, Louedec L, Heymes C, Ventura-Clapier R, Bedossa P et al. Effect of long-term heart rate reduction by If current inhibition on pressure overload-induced heart failure in rats. J Pharmacol Exp Ther 2008;324:43-49.
23. Deschepper CF, Llamas B. Hypertensive cardiac remodeling in males and females: from the bench to the bedside. Hypertension 2007;49:401- 407.
24. Wang DQ, Kakizoe E, Kobayashi Y, Shimoura K, Okunishi H. Differential suppression of pressure-overload cardiac and aortic hypertrophy in rats by angiotensin-converting enzyme inhibitors. Jpn J Pharmacol 1999;80: 333-342.
25. Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res 2003;26:89-95.
26. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50: 2357-2368.
27. Woodard Ge, Rosado JA. Recent advances in natriuretic peptide research. J Cell Mol Med 2007;11:1263-1271.
28. Schiffrin EL. Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scand Cardiovasc J Suppl 1998;47:15-21.
29. Passeri J, Bloch KD. Nitric oxide and cardiac remodeling. Heart Fail Clin 2005;1:175-186.
30. Marasciulo FL, Montagnani M, Potenza MA. Endothelin-1: the yin and yang on vascular function. Curr Med Chem 2006;13:1655-1665.
31. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
32. Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 1999;41:514-523.
33. Xie YW, Shen WQ, Zhao G, Xu XB, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Circ Res 1996;79:381-387.
34. Wollert KC, DrexLer H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002;7:317-325.
35. Kohan DE. Endothelin-1 and hypertension: from bench to bedside. Curr Hyoertens Rep 2008;10:65-69.
36. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007;76:8-18.
37. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005;37:2-12.
38. +ATP channels in adenosine-induced vasodilation on in vivo canine subendocardial arterioles. Am J Physiol 1999;277:H1931-H1939.
39. Ray CJ, Marshall JM. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J Physiol 2006;570: 85-96.
40. Xu JW, Ikeda K, Yamori Y. Upregulation of endothelial nitric oxide synthase by cyanidin-3-glucoside, a typical anthocyanin pigment. Hypertension 2004;44:217-222.
41. ATP in response to inotropic stress. Am J Physiol Heart Circ Physiol 2006;291: H152-H160.
42. ATP channel opener diazoxide. J Mol Cell Cardiol 2004;37: 1063-1067.
43. Gross GJ. Mitochondrial ATP-sensitive potassium channels and myocardial hypertrophy. J Mol Cell Cardiol 2005;38:237-239.
44. + on SH-SY5Y cells by decreasing extracellular glutamate level. J Neurochem 2005;94:1570-1579.
45. Chai Y, Niu L, Sun XL, Ding JH, Hu G. Iptakalim protects PC12 cell against H2O2-induced oxidative injury via opening mitochondrial ATP-sensitive potassium channel. Biochem Biophys Res Commun 2006;350:307-314.
46. Zeng Y, Long CL, Mu SF, Li YF, Wang H. Effects of diazoxide on membrane potential and respiration function of rat cardiac mitochondria. Chin J Clin Pharmacol Ther 2004;9:490-493.
47. ATP, PKCe, ROS, and MPT. Am J Physiol Heart Circ Physiol 2008; 295:H874-H882.
48. Ljubkovic M, Shi Y, Cheng Q, Bosnjak Z, Jiang MT. Cardiac mitochondrial ATP-sensitive potassium channel is activated by nitric oxide in vitro. FEBS Lett 2007;581:4255-4259.